RxDoctor Payments Data

David Robl, MD

Family Medicine · Wichita, KSNPI 1598873655

Payments from drug & device makers

$6,988in general payments, 2019–2025

Across 474 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$848
  • AbbVie$571
  • Boehringer Ingelheim$554
  • Lilly USA, LLC$534
  • Amgen$525
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,988 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$218,040
Medicare patients
359
Services billed
12,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$106,098
EliquisApixaban91$94,428
OzempicSemaglutide78$78,919
FarxigaDapagliflozin Propanediol56$54,684
JardianceEmpagliflozin21$23,666
XareltoRivaroxaban18$15,785
GemtesaVibegron14$15,425
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,890
TrulicityDulaglutide13$10,682
Breo ElliptaFluticasone/Vilanterol12$8,217
Tresiba Flextouch U-100Insulin Degludec28$7,553
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,236
Butorphanol Tartrate55$3,957
Albuterol Sulfate HfaAlbuterol Sulfate73$3,231
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen141$2,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$848$95,857119 claims
Novo NordiskOzempic$469$78,91978 claims
AstraZenecaFarxiga$1,003$54,68456 claims
Boehringer IngelheimJardiance$554$23,66621 claims
GSKTrelegy Ellipta, Breo Ellipta$79$21,10826 claims
Johnson & JohnsonXarelto$152$15,78518 claims
Sumitomo Pharma America, Inc.Gemtesa$87$15,42514 claims
Lilly USA, LLCTrulicity$534$10,68213 claims
AbbVieSynthroid$571$1,17221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →